Secondary cytoreductive surgery, hyperthermic intraperitoneal intraoperative chemotherapy, and chemotherapy alone: a retrospective comparison of alternative approaches in relapsed platinum sensitive ovarian cancer

Introduction: The best treatment for relapsed platinum sensitive epithelial ovarian cancer (EOC) is controversial. The aim of the study was to compare progression-free survival (PFS) and overall survival (OS) in platinum-sensitive EOC patients treated with chemotherapy alone (CTA), secondary cytoreductive surgery (SCR) or SCR plus hyperthermic intraperitoneal intraoperative chemotherapy (HIPEC). Materials and Methods: Retrospective analysis of the clinical outcome of 46 EOC patients with at least 30 months of follow-up. Results: Median follow-up time was 32 months for the CTA group, 30 months for the SCR group, and 45 months for the SCR + HIPEC group. Fifteen recurrences were observed in the CTA group, seven in the SCR group, and 16 in the SCR + HIPEC group. The median time elapsed between first and second recurrence (PFI-2) was significantly higher among patients treated with SCR + HIPEC, in comparison with patients treated with CTA (p = 0.012 and p = 0.017, respectively). On the contrary, PFI-2 did not significantly differ between the SCR and SCR + HIPEC groups (p = 0.877). A statistically significant difference in OS favouring SCR + HIPEC in comparison with CTA (p = 0.04) was observed. Conclusions: SCR ± HIPEC compared with CTA improves PFI-2 in patients with platinum-sensitive EOC recurrence. SCR + HIPEC might also improve OS in comparison with CTA. No improvement in favor of SCR + HIPEC vs SCR was observed,. These results further support the need of a randomized trial comparing chemotherapy with SCR ± HIPEC in this setting.

Secondary cytoreduction; HIPEC; Platinum sensitive relapse; Ovarian cancer; Platinum based chemotherapy; Cytoreductive surgery.

[1] Bafaloukos D., Linardou H., Aravantinos G., Papadimitriou C., Bamias A., Fountzilas G., et al.: “A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study”. BMC Medicine, 2010, 8, 3.

[2] Chang S.J., Bristow R.E.: “Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining 'optimal' residual disease”. Gynecol. Oncol., 2012, 125, 483.

[3] Boran N., Hizli D., Yilmaz S., Turan T., Celik B., Karabuk E., et al.: “Secondary cytoreductive surgery outcomes of selected patients with paclitaxel/platinum sensitive recurrent epithelial ovarian cancer”. J. Surg. Oncol., 2012, 106, 369.

[4] Luvero D., Milani A., Ledermann J.A.: “Treatment options in recurrent ovarian cancer: latest evidence and clinical potential”. Ther. Adv. Med. Oncol., 2014, 6, 229.

[5] Mutch D.G., Orlando M., Goss T., Teneriello M.G., Gordon A.N., McMeekin S.D., et al.: “Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer”. J. Clin. Oncol., 2007, 25, 2811.

[6] Galaal K., Naik R., Bristow R.E., Patel A., Bryant A., Dickinson H.O.: “Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer”. Cochrane Database Syst. Rev., 2010, 6, CD007822.

[7] Bristow R.E., Puri I., Chi D.S.: “Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis”. Gynecol. Oncol., 2009, 112, 265.

[8] Gungor M., Ortac F., Arvas M., Kosebay D., Sonmezer M., Kose K.: “The role of secondary cytoreductive surgery for recurrent ovarian cancer”. Gynecol. Oncol., 2005, 97, 74.

[9] Harter P., Hahmann M., Lueck H.J., Poelcher M., Wimberger P., Ortmann O., et al.: “Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis”. Ann. Surg. Oncol., 2009, 16, 1324.

[10] Lee C.K., Lord S., Grunewald T., Gebski V., Hardy-Bessard A.C., Sehouli J., et al.: “Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial”. Gynecol. Oncol., 2015, 136, 18.

[11] Chua T.C., Yan T.D., Saxena A., Morris D.L.: “Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality”. Ann. Surg., 2009, 249, 900.

[12] Fagotti A., Costantini B., Petrillo M., Vizzielli G., Fanfani F., Margariti P.A., et al.: “Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up”. Gynecol. Oncol., 2012, 127, 502.

[13] Cavaliere F., De Simone M., Virzi S., Deraco M., Rossi C.R., Garofalo A., et al.: “Prognostic factors and oncologic outcome in 146 patientswith colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O”. Eur. J. Surg. Oncol., 2011, 37, 148.

[14] Caneparo A., Massucco P., Vaira M., Maina G., Giovale E., Coggiola M., et al.: “Contamination risk for operators performing semiclosed HIPEC procedure using cisplatin. Eur J Surg Oncol: 2014;40(8):925.

[15] Yan T.D., Black D., Savady R., Sugarbaker P.H.: “A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei”. Ann. Surg. Oncol., 2007, 14, 484.

[16] Yan T.D., Black D., Savady R., Sugarbaker P.H.: “Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma”. J. Clin. Oncol., 2006, 24, 4011.

[17] Yan T.D., Welch L., Black D., Sugarbaker P.H.: “A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma”. Ann. Oncol., 2007, 18, 827.

[18] Jacquet P., Sugarbaker P.H.: “Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis”. Cancer Treat. Res., 1996, 82, 359.

[19] Sugarbaker P.H.: “Peritonectomy procedures”. Cancer Treat Res., 1996, 82, 235.

[20] De Simone M., Barone R., Vaira M., Aghemo B., Mioli P., Franco C., et al.: “Semi-closed hyperthermic-antiblastic peritoneal perfusion (HAPP) in the treatment of peritoneal carcinosis”. J. Surg. Oncol., 2003, 82, 138.

[21] Rustin G.J., Vergote I., Eisenhauer E., Pujade-Lauraine E., Quinn M., Thigpen T., et al.: “Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)”. Int. J. Gynecol. Cancer, 2011, 21, 419.

[22] Clavien P.A., Barkun J., de Oliveira M.L., Vauthey J.N., Dindo D., Schulick R.D., et al.: “The Clavien-Dindo classification of surgical complications: five-year experience”. Ann. Surg., 2009, 250, 187.

[23] Pfisterer J., Plante M., Vergote I., du Bois A., Hirte H., Lacave A.J., et al.: “Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergrouptrial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG”. J. Clin. Oncol., 2006, 24, 4699.

[24] Wagner U., Marth C., Largillier R., Kaern J., Brown C., Heywood M., et al.: “Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients”.Br. J. Cancer, 2012, 107, 588.

[25] Al Rawahi T., Lopes A.D., Bristow R.E., Bryant A., Elattar A., Chattopadhyay S., et al.: “Surgical cytoreduction for recurrent epithelial ovarian cancer”. Cochrane Database Syst. Rev., 2013, 2, CD008765.

[26] Harter P., Sehouli J., Reuss A., Hasenburg A., Scambia G., Cibula D., et al.: “Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO”. Int. J. Gynecol. Cancer, 2011, 21, 289.

[27] Oksefjell H., Sandstad B., Trope C.: ‘The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer”. Ann. Oncol., 2009, 20, 286.

[28] Spiliotis J., Vaxevanidou A., Sergouniotis F., Lambropoulou E., DatsisA., Christopoulou A.: “The role of cytoreductive su rgery and hyperthermicintraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study”. J. BUON., 2011, 16, 74.

[29] Munoz-Casares F.C., Rufian S., Rubio M.J., Diaz C.J., Diaz R., Casado A., et al.: “The role of hyperthermic intraoperative intra-peritoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer”. Clin. Transl. Oncol., 2009, 11, 753.

[30] Harrison M.L., Gore M.E., Spriggs D., Kaye S., Iasonos A., Hensley M., et al.: “Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials”. Gynecol. Oncol., 2007, 106, 469.